Enanta Pharmaceuticals
ENTA
122 hedge funds and large institutions have $397M invested in Enanta Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 47 increasing their positions, 38 reducing their positions, and 19 closing their positions.
174% more capital inflows, than outflows
Capital inflows: $91.2M | Capital outflows: $33.3M
92% more call options, than puts
Call options by funds: $655K | Put options by funds: $341K
24% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 38
1.47% more ownership
Funds ownership: 92.26% → 93.73% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 133 → 122 (-11)
37% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ADAR1 Capital Management
Austin,
Texas
|
+$17.4M |
| 2 |
SummitTX Capital
Fort Worth,
Texas
|
+$3.46M |
| 3 |
Goldman Sachs
New York
|
+$2.68M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.67M |
| 5 |
Spruce Street Capital
New York
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
-$6.89M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
-$6.1M |
| 3 |
Millennium Management
New York
|
-$3.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.85M |
| 5 |
Two Sigma Investments
New York
|
-$2.64M |
ENTA Hedge Fund Activity: Q2 2026 in Review
122 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2026, worth a combined $397M — up 17% from $338M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ENTA and 12 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 47 added.
The largest buyer was ADAR1 Capital Management, adding an estimated $17.4M. The largest seller was Deep Track Capital, cutting an estimated $6.89M.
- 122 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2026, down from 133 in Q1 2026.
- Funds reported $397M of Enanta Pharmaceuticals stock for Q2 2026, up 17% quarter-over-quarter.
- 12 funds opened new Enanta Pharmaceuticals positions in Q2 2026 and 19 closed out, a net change of -7 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2026 was ADAR1 Capital Management, an estimated $17.4M added.
- The largest Enanta Pharmaceuticals seller in Q2 2026 was Deep Track Capital, an estimated $6.89M sold.
Based on aggregated 13F filings for Q2 2026.